Product Description
Mechanisms of Action: HP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AiCuris
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Canada, France, Georgia, Germany, Greece, Israel, Italy, Mexico, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Communicable Diseases|Herpes Simplex
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AIC316-03-II-01 | P3 |
Unknown Status |
Herpes Simplex |
2025-11-30 |
|
| PRIOH-1 | P3 |
Recruiting |
Communicable Diseases|Herpes Simplex |
2025-01-01 |
|
| AIC316-03-I-07 | P1 |
Completed |
Herpes Simplex |
2023-05-18 |
53% |